Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Infections

Symptoms and General Pathology

Lung Neoplasms

COVID-19

Tuberculosis, Pulmonary

Coronavirus Infections

Hemoptysis

Pneumonia

Pneumonia, Viral

Communicable Diseases

Respiratory Tract Infections

Virus Diseases

Coronaviridae Infections

Nidovirales Infections

RNA Virus Infections

Lung Diseases

Respiratory Tract Diseases

Hemorrhage

Signs and Symptoms, Respiratory

patients with previous COVID-19 infection who underwent anatomic lung resection (segmentectomy, lobectomy, bilobectomy or pneumonectomy)

includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy

anatomic lung resection

Alexander H Tuliao, MD

This study will determine the outcomes of anatomic lung resections in patients who recovered from coronavirus disease 2019 (COVID-19) disease by describing the morbidity and mortality as well as the length of postoperative hospital stay.

This study will be conducted at the Lung Center of the Philippines. The study design is a retrospective case series implemented via chart review. Online and written patient records will be reviewed to determine the baseline patient characteristics and the preoperative outcomes. Patients who recovered from COVID-19 will be selected from those who underwent anatomic lung resection from June 1, 2020 to May 31, 2022. This study will be done in accordance with the Helsinky Declaration and Good Clinical Practice Guidelines, and will be subject for approval of the institutional Ethics and Technical Review Boards. Descriptive statistics will be used to describe patient characteristics and perioperative outcomes.

Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019

Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019 (COVID-19): a Two-Year Retrospective Case Series

Patient baseline characteristics and outcomes

proportion of patients who died due to perioperative complications

proportion of patients who develop acute kidney injury, acute myocardial infarction, acute respiratory distress syndrome (ARDS), acute respiratory failure, atelectasis requiring intervention, bronchopleural fistula, empyema thoracis, hemothorax, pneumonia, stroke or venous thromboembolism

proportion of patients who develop atrial fibrillation, pneumothorax or prolonged air leak

time duration from surgery to discharge order

Lung Center of the Philippines

Medical Officer III

Rare Diseases

Adenocarcinoma

Adenocarcinoma of Lung

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Adenocarcinoma

Fluoroscopy + RP-EBUS and consecutive lesion sampling by TBNA and/or TBB

Ultrathin bronchoscopy (MP190F; Olympus Medical Systems, Tokyo, Japan)

Alberto Fantin

Federico Mei, MD

Stefano Gasparini, MD

Roberto Piro, MD

Nicola Facciolongo, MD

Alberto Fantin, MD

Vincenzo Patruno, MD

The use of an ultrathin bronchoscope (UB) has recently been introduced in the diagnosis of peripheral lung lesions. The use of the UB can be supported by navigation systems such as fluoroscopy, ultrasound guidance, electromagnetic navigation, or other technologies, which have complementary potential. Further navigation techniques are still under study. The use of ultrathin instrumentation has already been shown to significantly reduce procedural times compared to traditional instrumentation.

The purpose of the study is to prospectively evaluate the institutional experience of different third-level hospital centers with the use of a UB (MP190F; Olympus Medical Systems, Tokyo, Japan) for sampling peripheral lung lesions by means of transbronchial needle aspiration (TBNA) or transbronchial biopsy (TBB), performed after fluoroscopic navigation and simultaneous radial probe-endobronchial ultrasound (RP-EBUS) assessment.

Design: multicentric, observational study.

Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions

Sensitivity, specificity, positive predictive value, negative predictive value

Comparison (% of concordant and % of discordant results) between R.O.S.E. (performed during the procedure by the pulmonologist or by the pathologist) and the final result obtained after the evaluation (by the pathologist) of the samples taken.

Patients will undergo two satisfaction questionnaires, set according to Likert scale, at the end of the endoscopic procedure.

Correlations will be made between the anesthetic, radiological and procedural parameters with respect to the answers obtained in the satisfaction questionnaires.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019	NCT05513248	COVID-19 Lung Cancer Lung TB Hemoptysis	anatomic lung r...	-	Lung Center of the Philippines
Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019	NCT05513248	COVID-19 Lung Cancer Lung TB Hemoptysis	anatomic lung r...	-	Lung Center of the Philippines
Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions	NCT05526573	Lung Cancer Lung; Node Lung Diseases Lung TB Lung Adenocarci... Lung Transplant...	Ultrathin bronc...	18 Years -	Azienda Sanitaria-Universitaria Integrata di Udine

Spots Global Cancer Trial Database for lung tb

Every month we try and update this database with for lung tb cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for lung tb

Every month we try and update this database with for lung tb cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for lung tb cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.